Patents by Inventor Robert Raffai

Robert Raffai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mouse Model of Chronic Heart Failure and Coronary Atherosclerosis Regression
    Publication number: 20080075663
    Abstract: An animal model has been developed where the animals can survive myocardial infarctions caused by diet-induced coronary atherosclerosis, and live with chronic heart failure. This animal model is a result of reduced activity of scavenger receptor class BI (SR-BI) and ApoE and the inducible activity of the Mx1-Cre gene. In a preferred embodiment, the model is a result of crossbreeding two transgenic mouse lines: a knockout of SR-BI (SRBI?/?) and an impaired ApoE expressor (Apoeh/h) to generate a strain referred to as Apoeh/hSRB1?/? mice, which is then crossbred to mice that carry the inducible Mx1-Cre transgene. The Apoeh/hSRB1?/? mouse model is genetically modified, enabling the offspring to rapidly and permanently lower their high blood cholesterol levels caused by dietary challenge.
    Type: Application
    Filed: June 19, 2007
    Publication date: March 27, 2008
    Inventors: Robert Raffai, Karl Weisgraber
  • Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
    Publication number: 20060230466
    Abstract: The invention provides gene-targeted non-human animals comprising a genetically modified apoE gene encodes a recombinant apoE polypeptide displaying domain interaction. The invention further provides cells isolated from the gene-targeted animals, which cells produce a recombinant apoE polypeptide displaying domain interaction. The invention further provides methods of identifying agents that reduce apoE4 domain interaction, and which are useful to treat apoE4-related neurological and cardiovascular disorders.
    Type: Application
    Filed: June 7, 2006
    Publication date: October 12, 2006
    Inventors: Karl Weisgraber, Robert Farese, Robert Raffai, Li-Ming Dong
  • Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
    Patent number: 7081561
    Abstract: The invention provides gene-targeted non-human animals comprising a genetically modified apoE gene encodes a recombinant apoE polypeptide displaying domain interaction. The invention further provides cells isolated from the gene-targeted animals, which cells produce a recombinant apoE polypeptide displaying domain interaction. The invention further provides methods of identifying agents that reduce apoE4 domain interaction, and which are useful to treat apoE4-related neurological and cardiovascular disorders.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: July 25, 2006
    Assignee: The Regents of the University of California
    Inventors: Karl H. Weisgraber, Robert V. Farese, Robert Raffai, Li-Ming Dong
  • Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof
    Publication number: 20020194628
    Abstract: The invention provides gene-targeted non-human animals comprising a genetically modified apoE gene encodes a recombinant apoE polypeptide displaying domain interaction. The invention further provides cells isolated from the gene-targeted animals, which cells produce a recombinant apoE polypeptide displaying domain interaction. The invention further provides methods of identifying agents that reduce apoE4 domain interaction, and which are useful to treat apoE4-related neurological and cardiovascular disorders.
    Type: Application
    Filed: December 14, 2001
    Publication date: December 19, 2002
    Inventors: Karl H. Weisgraber, Robert V. Farese, Robert Raffai, Li-Ming Dong